Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 1 Safety Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors
This study is currently recruiting participants.
Verified July 2012 by Xcovery Holding Company, LLC
Study NCT01625234   Information provided by Xcovery Holding Company, LLC

First Received on June 15, 2012.   Last Updated on July 25, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Solid Tumors
Additional conditions recognized in this trial
Neoplasms
Interventions listed in this trial
X-396
Sponsors listed in this trial
Xcovery Holding Company, LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services